As is too often true, the biggest hurdle is money. Vaccines cost hundreds of millions of dollars to develop, test, and bring to market. Human trials involve thousands of subjects. “It’s difficult to get companies to partner in trials,” Sacks told me. “They don’t see any market in it, because the people who have leishmaniasis have no money.”
